TCGA-97-7554-01A-11R-2039-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 83
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- INTERFERON_ALPHA_RESPONSE+0.440
- TGF_BETA_SIGNALING+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- UV_RESPONSE_DN+0.410
- INTERFERON_GAMMA_RESPONSE+0.400
- NOTCH_SIGNALING+0.350
- ANGIOGENESIS+0.330
- APICAL_JUNCTION+0.330
- INFLAMMATORY_RESPONSE+0.320
Top 10 suppressed
- MYC_TARGETS_V2-0.420
- E2F_TARGETS-0.390
- OXIDATIVE_PHOSPHORYLATION-0.370
- MYC_TARGETS_V1-0.320
- G2M_CHECKPOINT-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- KRAS_SIGNALING_DN-0.230
- FATTY_ACID_METABOLISM-0.180
- MTORC1_SIGNALING-0.170
- P53_PATHWAY-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-8055-01A-11R-2241-07 | — | cohortA1 | 0.894 |
| 2 | efe57fc7-7cf4-432b-86ff-9fd2d1a37b5e | — | — | 0.886 |
| 3 | TCGA-64-1679-01A-21R-2066-07 | — | cohortA1 | 0.882 |
| 4 | TCGA-55-6712-01A-11R-1858-07 | — | cohortA1 | 0.875 |
| 5 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.872 |
| 6 | TCGA-AR-A24V-01A-21R-A169-07 | — | A | 0.871 |
| 7 | TCGA-69-7761-01A-11R-2170-07 | — | cohortA1 | 0.869 |
| 8 | TCGA-44-6775-01A-11R-1858-07 | — | cohortA1 | 0.867 |
| 9 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.866 |
| 10 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |